NBIX FY2025 EPS Forecast Increased by Cantor Fitzgerald

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Investment analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of Neurocrine Biosciences in a research report issued to clients and investors on Thursday, July 31st. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings of $4.50 per share for the year, up from their prior estimate of $4.39. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share.

Other equities analysts have also issued research reports about the company. UBS Group increased their target price on Neurocrine Biosciences from $152.00 to $174.00 and gave the stock a “buy” rating in a research note on Wednesday, July 9th. Needham & Company LLC increased their price target on shares of Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a “buy” rating in a research report on Tuesday, May 6th. Canaccord Genuity Group raised their price objective on shares of Neurocrine Biosciences from $158.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, May 6th. BMO Capital Markets lifted their price objective on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the company a “market perform” rating in a report on Tuesday, May 6th. Finally, Wall Street Zen upgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a report on Saturday. Four investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $164.00.

Neurocrine Biosciences Stock Up 0.5%

NBIX opened at $128.91 on Friday. Neurocrine Biosciences has a 52 week low of $84.23 and a 52 week high of $157.40. The business has a fifty day simple moving average of $128.26 and a 200-day simple moving average of $121.03. The firm has a market cap of $12.76 billion, a P/E ratio of 38.14, a P/E/G ratio of 1.32 and a beta of 0.24.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.08. The firm had revenue of $687.50 million during the quarter, compared to the consensus estimate of $653.09 million. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The firm’s revenue for the quarter was up 16.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.63 EPS.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 59,819 shares of the firm’s stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the transaction, the insider owned 18,289 shares of the company’s stock, valued at approximately $2,385,982.94. This trade represents a 76.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kevin Charles Gorman sold 9,613 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total value of $1,157,212.94. Following the sale, the director owned 514,596 shares in the company, valued at $61,947,066.48. This trade represents a 1.83% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 120,251 shares of company stock worth $14,978,602. Corporate insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in NBIX. Motley Fool Asset Management LLC lifted its stake in Neurocrine Biosciences by 8.5% in the second quarter. Motley Fool Asset Management LLC now owns 2,667 shares of the company’s stock valued at $335,000 after buying an additional 209 shares during the last quarter. Envestnet Asset Management Inc. grew its position in shares of Neurocrine Biosciences by 61.9% during the second quarter. Envestnet Asset Management Inc. now owns 198,039 shares of the company’s stock worth $24,891,000 after acquiring an additional 75,733 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Neurocrine Biosciences by 15.7% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 16,195 shares of the company’s stock valued at $2,036,000 after acquiring an additional 2,202 shares during the period. Brighton Jones LLC purchased a new stake in Neurocrine Biosciences in the 2nd quarter valued at $351,000. Finally, Linden Thomas Advisory Services LLC raised its position in Neurocrine Biosciences by 1.5% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 6,699 shares of the company’s stock valued at $842,000 after purchasing an additional 96 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.